Jan 29, 2007<\/p>\n
N. Parthasarathi
\nAmbassador
\nIndian Embassy in Seoul
\n37-3, Hannam-Dong Yongsan-ku,
\nSeoul, South Korea<\/p>\n
Re : The Norvatis’ legal action in India on the Patent Law<\/p>\n
Dear Ambassador N. Parthasarathi<\/p>\n
On behalf of the 27 Korean NGOs, Trade Unions, I am writing to express our concerns regarding the legal proceedings that Norvatis initiated in India in May 2006, challenging the rejection of its patent application for imatinib mesylate (Gleevec\/Glivec) as well as questioning the compliance of the Indian Patents Act with the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights(TRIPS).<\/p>\n
This action contradicts the WTO Doha Declaration on the TRIPS Agreement and Public Health that states that “…the Agreement can and should be interpreted and implemented in a manner supportive of WTO Members’ right to protect public health and, in particular, to promote access to medicines for all”
\nThe same declaration allows countries to take measures to protect public health.<\/p>\n
But Norvatis is challenging a public health safeguard enshrined within India’s Patents Act. This would have a devastating impact on people around the world who rely on affordable medicines manufactured in India.
\nSo patients and healthcare groups around the world are watching carefully this case and the next steps the Indian government will take.<\/p>\n
Therefore we are requesting your government not to allow multinational drug companies to improperly extend their monopolies, which result in higher price of important medicines out of reach for the majority of Indians and the patients in the developing countries.<\/p>\n
We will fight with you against the greed of multinational companies.
\nThank you for your consideration.<\/p>\n
Best regards,<\/p>\n
Endorsed by :<\/p>\n
Consolidation for Medical Consumer
\nDemocratic Labor Party
\nHealth Right Network
\nIntellectual Property Left
\nKorean Confederation of Trade Unions
\nKorean Federation of Medical Groups for Health Rights (KFHR)
\nAssociation of Korea Doctors for Health Rights
\nAssociation of Physicians for Humanism
\nKorea Dentists Association for Health Society
\nKorea Health and Medical Workers Union
\nKorean Pharmacists for Democratic Society
\nKorean Health & Medical Workers’ Union
\nKorean Progressive Network Jinbonet
\nKorean Social Insurance Union
\nLesbian Counseling Center in South Korea
\nNanuri+, HIV\/AIDS Human Rights Advocacy Group of Korea
\nKorean Gay Men’s Human Rights Group
\nPublic Pharmaceutical Center
\nSarangbang, Group for Human Rights
\nSolidarity for Lesbian Gay Bisexual Transgender Human Rights of Korea
\nPatient Group Combination for Patient Right
\nKorea ankylosing Spondylitis
\nKorea Encephaloma Patient Group
\nKorea GIST Patient Group
\nKorea Leukemia Patient Group
\nKorea RCC Patient Group
\nPeople’s Solidarity for Social Progress<\/p>\n
2007-01-28<\/p>\n","protected":false},"excerpt":{"rendered":"
On behalf of the 27 Korean NGOs, Trade Unions, I am writing to express our concerns regarding the legal proceedings that Norvatis initiated in India in May 2006, challenging the rejection of its patent application for imatinib mesylate (Gleevec\/Glivec) as well as questioning the compliance of the Indian Patents Act with the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights(TRIPS). <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,12,3731],"tags":[3190,3045,1328,3202,534,1325],"class_list":{"0":"post-5747","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-17","7":"category-12","8":"category-3731","9":"tag-3190","10":"tag-3045","11":"tag-1328","12":"tag-3202","13":"tag-534","14":"tag-1325"},"jetpack_featured_media_url":"","jetpack-related-posts":[{"id":3794,"url":"https:\/\/act.jinbo.net\/wp\/3794\/","url_meta":{"origin":5747,"position":0},"title":"[Letter] Joint Letter of Korean NGOs to the Indian Embassy in Seoul","author":"\ub514\uc815\ub137","date":"2007\/01\/29","format":false,"excerpt":"Jan 29, 2007 N. Parthasarathi Ambassador Indian Embassy in Seoul 37-3, Hannam-Dong Yongsan-ku, Seoul, South Korea Re : The Norvatis' legal action in India on the Patent Law Dear Ambassador N. Parthasarathi","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":3793,"url":"https:\/\/act.jinbo.net\/wp\/3793\/","url_meta":{"origin":5747,"position":1},"title":"[Letter] Joint Letter of Korean NGOs to the Norvatis","author":"\ub514\uc815\ub137","date":"2007\/01\/29","format":false,"excerpt":"Jan 29, 2007 Daniel Vasella, MD CEO, Norvatis Postfach CH-4002, Basel, Switzerland Re : Norvatis' legal action in India on the Patent Law Dear Sir","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":5823,"url":"https:\/\/act.jinbo.net\/wp\/5823\/","url_meta":{"origin":5747,"position":2},"title":"Patents and Profit: Gleevec Price Talks Break Down.","author":"\ub514\uc815\ub137","date":"2002\/11\/07","format":false,"excerpt":"The National Health Insurance System Board held talks on September 6 to try decide the retail price of Gleevec, a cancer drug used for treating leukemia, only to end by delaying the talks even further. One year has passed since the problem of Gleevec first arose.","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":6687,"url":"https:\/\/act.jinbo.net\/wp\/6687\/","url_meta":{"origin":5747,"position":3},"title":"Stop the India-EU FTA Negotiations, Decimator of the ‘Pharmacy of the World’!","author":"\ub514\uc815\ub137","date":"2011\/11\/28","format":false,"excerpt":"US and EU are threatening lives of people living with disease now. The India-EU FTA is an agreement which risk patients' health none the more than the KORUS FTA. Especially, the India-EU FTA endangers lives of people living with disease all over the world. We urge the Lee Myoung-bak government\u2026","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":5752,"url":"https:\/\/act.jinbo.net\/wp\/5752\/","url_meta":{"origin":5747,"position":4},"title":"Struggle for Access to Glivec","author":"\ub514\uc815\ub137","date":"2003\/09\/24","format":false,"excerpt":"Struggle for Access to Glivec in South Korea Solidarity Needed Now!!!","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":7482,"url":"https:\/\/act.jinbo.net\/wp\/7482\/","url_meta":{"origin":5747,"position":5},"title":"[Joint Statement] Novartis defeated in its appeal trial, a triumphant victory of World patients fighting back Patent Exclusivity – Welcome the ruling of the Supreme Court of India","author":"\ub514\uc815\ub137","date":"2013\/04\/03","format":false,"excerpt":"The protracted Novartis\u2019 appeal from 2006 for a patent to Gleevec (Leukemia medicine), and against Indian Patent law has finally reached a conclusion. On Apr1, Indian Supreme court dismissed Novartis\u2019 appeal.","rel":"","context":""English"\uc5d0\uc11c","block_context":{"text":"English","link":"https:\/\/act.jinbo.net\/wp\/cat\/1\/17\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/posts\/5747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/comments?post=5747"}],"version-history":[{"count":2,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/posts\/5747\/revisions"}],"predecessor-version":[{"id":28032,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/posts\/5747\/revisions\/28032"}],"wp:attachment":[{"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/media?parent=5747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/categories?post=5747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/act.jinbo.net\/wp\/wp-json\/wp\/v2\/tags?post=5747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}